טוען...
Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma
BACKGROUND: Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary anti-androgen treatment through a neuroendocrine phenotype. While prior studies comparing NEPC and prostatic adenocarcinoma have iden...
שמור ב:
| הוצא לאור ב: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683385/ https://ncbi.nlm.nih.gov/pubmed/29132337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3729-z |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|